Arcturus therapeutics and cystic fibrosis foundation extend agreement to advance arct-032, an investigational messenger rna (mrna) therapeutic to treat cystic fibrosis

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, announced today that arcturus and the cystic fibrosis foundation (cf foundation) have extended their ongoing agreement. the cf foundation agreed to increase its financial commitment to ~$25 million to advance ar.
ARCT Ratings Summary
ARCT Quant Ranking